High mobility group box-1 and its clinical value in breast cancer

Abstract

BackgroundHigh mobility group box-1 (HMGB1) is a factor regulating malignant tumorigenesis, proliferation, and metastasis, and is associated with poor clinical pathology in various human cancers. We investigated the differential concentrations of HMGB1 in tissues and sera, and their clinical value for diagnosis in patients with breast cancer, benign breast disease, and healthy individuals.MethodsHMGB1 levels in tumor tissues, adjacent normal tissues, and benign breast disease tissues was detected via immunohistochemistry. Serum HMGB1 was measured using an enzyme-linked immunosorbent assay in 56 patients with breast cancer, 25 patients with benign breast disease, and 30 healthy control subjects. The clinicopathological features of the patients were compared. Tissues were evaluated histopathologically by pathologists.ResultsHMGB1 levels in the tissues and sera of patients with breast cancer were significantly higher than those in patients with benign breast disease or normal individuals. The 56 cancer patients were classified as having high tissue HMGB1 levels (n=41) or low tissue HMGB1 levels (n=15), but the corresponsive serum HMGB1 in these two groups was not significantly different. HMGB1 levels in breast cancer tissues significantly correlated with differentiation grade, lymphatic metastasis, and tumor-node-metastasis stage, but not patient age, tumor size, or HER-2/neu expression; no association between serum HMGB1 levels and these clinicopathological parameters was found. The sensitivity and specificity of tissue HMGB1 levels for the diagnosis of breast cancer were 73.21% and 84.00%, respectively, while positive and negative predictive values were 91.11% and 58.33%.ConclusionHMGB1 might be involved in the development and progression of breast cancer and could be a supportive diagnostic marker for breast cancer. Serum HMGB1 could be a useful serological biomarker for diagnosis and screening of breast cancer.

Multiplex Gene Expression Profiling of 16 Target Genes in Neoplastic and Non-Neoplastic Canine Mammary Tissues Using Branched-DNA Assay

“…The genes MAPK3 , HMGB1 , HMGA1 , PIK3CA , and MCL1 are genes known to stimulate cellular growth; however, contrary to what is normally reported in humans [ 46 , 47 , 48 , 49 , 50 ], in the present study these genes were shown to be consistently expressed at lower levels in malignant tumors. Therefore, it is hypothesized that those genes play a different role in canine mammary tumors.…”

The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer

“…Several studies report that HMGB1 plays a key role in various types of malignancies, such as breast cancer [ 40 ], gastric cancer [ 41 ] and hepatocellular carcinoma [ 42 ]. However, certain factors remain unclear that are related to the overexpression and prognosis of HMGB1 in NSCLC.…”

The dual role and therapeutic potential of high-mobility group box 1 in cancer

“…HMGB1 is highly expressed in most tumor types. Previous studies found that the expression of HMGB1 was much higher in tumor than in the normal tissue counterpart, such as hepatocellular carcinoma [ 15 ], breast carcinomas [ 43 ] and colorectal adenocarcinomas [ 44 ]. However, certain cancers such as adrenal gland carcinoma contain no HMGB1 protein [ 38 ].…”